CoChat
Sign Up
Cited by 55Bariatric Surgery and OutcomesDiabetes Treatment and ManagementMinimally Invasive Surgical Techniques

Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results

Open access
van Baar, Annieke C.G., Beuers, Ulrich, Wong, Kari, Haidry, Rehan, Costamagna, Guido, Hafedi, Alia, Deviere, Jacques, Ghosh, Soumitra S. +5 more·2019·JHEP Reports
DOI 10.1016/j.jhepr.2019.10.006PMC PMC7005649
Open this paper in CoChat — free account

Abstract

Background & Aims Insulin resistance is a core pathophysiological defect underscoring type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Both conditions improve with duodenal exclusion surgery. Duodenal mucosal resurfacing (DMR) is an endoscopic intervention developed to treat metabolic disease which has been shown to improve glycaemia in patients with poorly controlled T2DM. Herein, we aimed to further analyse the effects of DMR on hepatic and metabolic parameters in this patient cohort. Methods Eighty-five patients with T2DM who received endoscopic DMR treatment were enrolled from 5 centres and followed up for 6 months. We assessed safety in all patients. Efficacy was evaluated in patients who received at least 9 cm of duodenal ablation (n = 67). Endpoints included HbA1c, fasting plasma glucose, weight and aminotransferase levels. Metabolomic analysis was conducted in a subgroup (n = 14). Data were analysed using paired t test or ANOVA for repeated measures with Bonferroni correction and correction for initial weight loss if applicable. Results The DMR procedure was completed with no intraprocedural complications in the entire cohort. HbA1c was lower 6 months after DMR than at baseline (7.9 ± 0.2% vs. 9.0 ± 0.2% [mean ± SE], p ≪0.001). Fasting plasma glucose was also significantly lower 6 months after DMR compared to baseline (161 ± 7 mg/dl vs. 189 ± 6 mg/dl, p = 0.005). Body weight decreased slightly. At 6 months, alanine aminotransferase had decreased from 41 ± 3 IU/L to 29 ± 2 IU/L ( p ≪0.001) and aspartate aminotransferase had decreased from 30 ± 2 IU/L to 23 ± 1 IU/L ( p ≪0.001). Metabolomic analysis demonstrated that DMR had key lipid-lowering, insulin-sensitizing and anti-inflammatory effects, as well as increasing antioxidant capacity. Mean FIB-4 was also markedly decreased. Conclusion Hydrothermal ablation of the duodenum by DMR elicits a beneficial metabolic response in patients with T2DM. DMR also improves hepatic indices, potentially through an insulin-sensitizing mechanism. These encouraging data deserve further evaluation in randomized controlled trials. Lay summary Hydrothermal duodenal mucosal resurfacing (DMR) is an endoscopic technique designed to treat metabolic disease through ablation of the duodenal mucosa. DMR is a safe procedure which improves glycaemia and hepatic indices in patients with type 2 diabetes mellitus. DMR is an insulin-sensitizing intervention which can be complementary to lifestyle intervention approaches and pharmacological treatments aimed at preserving the pancreas and liver from failure. DMR is a potential therapeutic solution for patients with type 2 diabetes and fatty liver disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhepr.2019.10.006

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. [1]NCD Risk Factor Collaboration Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants Lancet 387 2016 1513 1530 27061677 PMC5081106
  2. [2]Saponaro C Gaggini M Gastaldelli A Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms Curr Diab Rep 15 2015 607 25894944
  3. [3]Williamson RM Price JF Glancy S Perry E Nee LD Hayes PC Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study Diabetes Care 34 2011 1139 1144 21478462 PMC3114489
  4. [4]Resnick HE Foster GL Bardsley J Ratner RE Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey Diabetes Care 29 2006 531 537 16505501
  5. [5]Adams LA Lymp JF St Sauver J Sanderson SO Lindor KD Feldstein A The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 2005 113 121 16012941
  6. [6]Charlton MR Burns JM Pedersen RA Watt KD Heimbach JK Dierkhising RA Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253 21726509
  7. [7]Lallukka S Yki-Jarvinen H Non-alcoholic fatty liver disease and risk of type 2 diabetes Best Pract Res Clin Endocrinol Metab 30 2016 385 395 27432073
  8. [8]Portillo-Sanchez P Bril F Maximos M Lomonaco R Biernacki D Orsak B High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels J Clin Endocrinol Metab 100 2015 2231 2238 25885947 PMC6287506
  9. [9]Chalasani N Younossi Z Lavine JE Diehl AM Brunt EM Cusi K The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609 22656328
  10. [10]Joo SK Kim W Kim D Kim JH Oh S Lee KL Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease Liver Int 2017 28796410
  11. [11]Shah AG Lydecker A Murray K Tetri BN Contos MJ Sanyal AJ Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 7 2009 1104 1112 19523535 PMC3079239
  12. [12]Schauer PR Bhatt DL Kirwan JP Wolski K Aminian A Brethauer SA Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes N Engl J Med 376 2017 641 651 28199805 PMC5451258
  13. [13]Mingrone G Cummings DE Changes of insulin sensitivity and secretion after bariatric/metabolic surgery Surg Obes Relat Dis 12 2016 1199 1205 27568471
  14. [14]Mummadi RR Kasturi KS Chennareddygari S Sood GK Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis Clin Gastroenterol Hepatol 6 2008 1396 1402 18986848
  15. [15]Verdam FJ Greve JW Roosta S van Eijk H Bouvy N Buurman WA Small intestinal alterations in severely obese hyperglycemic subjects J Clin Endocrinol Metab 96 2011 E379 E383 21084402
  16. [16]Ferrannini E Mingrone G Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes Diabetes Care 32 2009 514 520 19246589 PMC2646039
  17. [17]Salinari S Carr RD Guidone C Bertuzzi A Cercone S Riccioni ME Nutrient infusion bypassing duodenum-jejunum improves insulin sensitivity in glucose-tolerant and diabetic obese subjects Am J Physiol Endocrinol Metab 305 2013 E59 E66 23651846
  18. [18]Dirksen C Hansen DL Madsbad S Hvolris LE Naver LS Holst JJ Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report Diabetes Care 33 2010 375 377 19918005 PMC2809286
  19. [19]Shimizu H Eldar S Heneghan HM Schauer PR Kirwan JP Brethauer SA The effect of selective gut stimulation on glucose metabolism after gastric bypass in the Zucker diabetic fatty rat model Surg Obes Relat Dis 10 2014 29 35 23507630
  20. [20]Gniuli D Calcagno A Dalla Libera L Calvani R Leccesi L Caristo ME High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats Diabetologia 53 2010 2233 2240 20585935
  21. [21]Rajagopalan H Cherrington AD Thompson CC Kaplan LM Rubino F Mingrone G Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study Diabetes Care 2016 27519448
  22. [22]van Baar ACG Holleman F Crenier L Haidry R Magee C Hopkins D Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study Gut 2019 PMC6984054 31331994
  23. [23]Storey JD Tibshirani R Statistical significance for genomewide studies Proc Natl Acad Sci U S A 100 2003 9440 9445 12883005 PMC170937
  24. [24]Nocito L Kleckner AS Yoo EJ Jones Iv AR Liesa M Corkey BE The extracellular redox state modulates mitochondrial function, gluconeogenesis, and glycogen synthesis in murine hepatocytes PLoS One 10 2015 e0122818 PMC4376787 25816337
  25. [25]Tonks KT Coster AC Christopher MJ Chaudhuri R Xu A Gagnon-Bartsch J Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans Obesity (Silver Spring) 24 2016 908 916 26916476 PMC6585800
  26. [26]Adeva-Andany M Lopez-Ojen M Funcasta-Calderon R Ameneiros-Rodriguez E Donapetry-Garcia C Vila-Altesor M Comprehensive review on lactate metabolism in human health Mitochondrion 17 2014 76 100 24929216
  27. [27]Gall WE Beebe K Lawton KA Adam KP Mitchell MW Nakhle PJ alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population PLoS One 5 2010 e10883 PMC2878333 20526369
  28. [28]Puri P Wiest MM Cheung O Mirshahi F Sargeant C Min HK The plasma lipidomic signature of nonalcoholic steatohepatitis Hepatology 50 2009 1827 1838 19937697 PMC5031239
  29. [29]Narasimhan S Gokulakrishnan K Sampathkumar R Farooq S Ravikumar R Mohan V Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes Clin Biochem 43 2010 815 821 20398645
  30. [30]Yamanouchi T Ogata N Tagaya T Kawasaki T Sekino N Funato H Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control Lancet 347 1996 1514 1518 8684103
  31. [31]Nerby CL Stickle DF 1,5-anhydroglucitol monitoring in diabetes: a mass balance perspective Clin Biochem 42 2009 158 167 18804100

Cited by

Sorted by citations

Authors
van Baar, A. C. G., Beuers, U., Wong, K., Haidry, R., Costamagna, G., Hafedi, A., Deviere, J., Ghosh, S. S., Lopez-Talavera, J. C., Rodriguez, L., Galvao Neto, M. P., Sanyal, A., & Bergman, J. J. G. H. M.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Metabolon (United States) (US)
  • University College Hospital (GB)
  • Università Cattolica del Sacro Cuore (IT)
  • Erasmus Hospital (BE)
  • Virginia Commonwealth University (US)
Corresponding author
Bergman, Jacques J.G.H.M.
ORCID
Venue
JHEP Reports
Publisher
Elsevier BV
Published
2019-12
Volume
1
Issue
6
Pages
429-437
ISSN
2589-5559 (ISSN-L)
DOI
10.1016/j.jhepr.2019.10.006
PMC
PMC7005649
OpenAlex
W2984051241
Cited by
55
References
0
Citations by year
2026: 5 · 2025: 8 · 2024: 11 · 2023: 3 · 2022: 7 · 2021: 13 · 2020: 7 · 2019: 1
FWCI
6.69
Type
journal article
Language
en
Update notices
erratum (2024-06-01)
Open access
Licence
Locations
  • JHEP Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Minimally Invasive Surgical Techniques
Keywords
duodenal mucosal resurfacing, type 2 diabetes, non-alcoholic fatty liver disease, insulin resistance, glycemic control, HbA1c, fasting blood glucose, transaminases, liver enzymes, FIB-4, metabolomics, hypolipidemic effect, antioxidant capacity, anti-inflammatory activity, endoscopic treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review